Shares of Shilpa Medicare Ltd were trading almost 5% higher on 15 May after the company secured an Establishment Inspection Report (EIR) from the United...
Shilpa Medicare, in partnership with the Zydus Group through their joint venture Oncosol, and its collaborator Shorla Oncology, announced on November 27 that the USFDA...
Shilpa Medicare on Tuesday, 19 November, announced receiving a suitability certificate for its active pharmaceutical ingredient (API), Octreotide, from a European regulatory authority. In its...
The shares of Shilpa Medicare Ltd skyrocketed 11% on 26 August following the company’s announcement of a positive result in Phase 3 trials for SMLNUD07,...
Shilpa Medicare, on Tuesday, 25 June, announced that the US Food and Drug Administration (FDA) has successfully concluded an inspection of the company’s Bio-Analytical Laboratory,...
Shares of Shilpa Medicare were trading 3% higher on 3 November after the company announced acquiring United States-based Pilnova Pharma, which has now become the...
Shilpa Medicare announced on 4 September that it had received approval from the UK healthcare products regulator to market a Meniere’s syndrome drug. The company...